Collecting Tumor Samples to Test a Platform That Predicts Immunotherapy Response
Collects tumor tissue from adults with several cancers to test a response prediction tool.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Jacksonville, Phoenix, and Rochester, United StatesSee the 3 sites
- Trial code
- Registry title
- Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- Status
- Recruiting
- People taking part
- 324 people, planned
- Started
- 24 Apr 2024
- Expected to end
- May 2027
- Type of study
- Observational
- Treatments tested
- Biospecimen Collection
- Tissue Collection
- Record updated
- 12 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain advanced or early-stage solid tumors who are about to get, or are planning to get, immune checkpoint inhibitor treatment. It collects tumor tissue for research.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Stage IV, metastatic or recurrent cancers of the lung (NSCLC), skin, esophagus, cervix, endometrium, liver, or colon (dMMR only). Also kidney (clear cell) or bladder (urothelial) cancer at stage III or IV. Also early-stage triple-negative breast cancer or NSCLC before surgery. Measurable disease is needed for locally advanced or metastatic cancer.
- Earlier treatment
- People newly diagnosed must not have had treatment before the biopsy. People whose cancer spread after an earlier stage must have had no anti-cancer treatment for at least 2 - 4 weeks before the biopsy.
- Biomarker or test result
- Any solid tumor with high tumor mutation burden (TMB), microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) can also join.
Main reasons for not taking part
- Pregnant women
- Weakened immune system, or HIV positive and taking antiretroviral therapy
- Uncontrolled illness, such as an active infection
- Severe other illness that the investigator judges a problem for the biopsy
- Enrolled in, or planning to join, a blinded cancer treatment trial
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Subjects must meet one of the following criteria:
- Subjects suspected of or diagnosed with the following Stage IV/metastatic or recurrent malignancies:; Lung: Non-small Cell Lung Cancer (NSCLC); Skin: Cutaneous Malignancy, excluding Uveal Melanoma; Esophageal Cancer; Cervical Cancer; Endometrial Cancer; Colon Cancer: Mismatch repair deficient (dMMR) CRC only; All solid tumors with high tumor mutation burden (TMB); All solid tumors that are microsatellite instability high (MSI-H); All mismatch repair deficient (dMMR) solid tumors; Liver Cancer; Any solid tumor with measurable disease that is eligible for pure ICI therapy or that the clinician plans to treat with immune checkpoint inhibitor (ICI) therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate laboratory developed tests (LDTs) that, per clinician, render the patient eligible for ICI therapy, either frontline or a later line; OR
- Subjects suspected of or diagnosed with the following Stage III per provider discretion or IV/metastatic malignancies:; Kidney: Clear Cell Renal Cell Carcinoma (ccRCC); Bladder: Urothelial Carcinoma (UC); Any solid tumor with measurable disease that is eligible for pure ICI therapy or that the clinician plans to treat with ICI therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate LDT tests that per clinician, render the patient eligible for ICI therapy, either frontline or a later line; OR
- Patients who will be receiving neoadjuvant CPI for the following resectable early-stage malignancies:; Breast Cancer: Triple negative breast cancer (TNBC); Lung: Non-small cell lung cancer (NSCLC); NOTE: Patients with suspected NSCLC who would be eligible for neoadjuvant checkpoint inhibitor (CPI) are eligible to enroll per provider discretion; Any solid tumor that is eligible for pure ICI therapy or that the clinician plans to treat with ICI therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate LDT tests that per clinician, render the patient eligible for ICI therapy, either frontline or a later line
- LOCALLY ADVANCED/METASTATIC PATIENTS: Measurable disease as defined per protocol NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible
- NEOADJUVANT PATIENTS: Subjects must be eligible based on investigator discretion to receive approved CPI therapy
- Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy
- Subjects who are Stage I, II, or III and have progressed to metastatic cannot have received any anti-cancer treatment for at least 2 - 4 weeks (depending upon the washout period of prior anti-cancer treatment) prior to biopsy as per the agents used
- ECOG Performance Status (PS) 0, 1 or 2
- Negative pregnancy test done ≤7 days prior to enrollment, for persons of childbearing potential only
- Female subjects must not be pregnant or breastfeeding and must use appropriate methods of contraception when applicable
- Subjects must be clinically able, at investigator discretion, and willing to undergo either:; additional biopsy passes during their standard of care biopsy, OR; a biopsy for research only, if applicable; NOTE: These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to biopsies per the clinician
- Subjects with a known secondary cancer diagnosis are eligible to participate if participation does not interfere with systemic anti-cancer standard of care treatment for suspected primary diagnosis
- Provide written informed consent
Who cannot take part
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety for the biopsy
- Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
- Uncontrolled intercurrent illness including, but not limited to:; ongoing or active infection; psychiatric illness/social situations that would limit compliance with study requirements
- Subjects who are enrolled or plan to be enrolled in a blinded cancer therapeutic treatment trial
- Pregnant women because this study involves a greater than minimal risk procedure (biopsy)
Where in United States
- Mayo Clinic in FloridaJacksonville, United StatesContact: Clinical Trials Referral OfficeTaking people
- Mayo Clinic in ArizonaPhoenix, United StatesContact: Clinical Trials Referral OfficeTaking people
- Mayo Clinic in RochesterRochester, United StatesContact: Clinical Trials Referral OfficeTaking people
About the trial
What the trial wants to find out
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
The group in the trial
- Observational
Patients undergo tissue biopsy and may optionally undergo blood sample collection and have their medical records reviewed on study. Patients receive standard treatment with checkpoint inhibitors during the study and undergo standard tumor assessments during screening and follow-up.
Treatment: Biospecimen Collection and Tissue Collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
- Plain-language title
- Collecting Tumor Samples to Test a Platform That Predicts Immunotherapy ResponseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity.Journal of translational medicine, 2026
- A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity.bioRxiv : the preprint server for biology, 2025
- Record updated
- 12 March 2026